[1]
Liu L, Gao Z, Yang Y, et al. Economic variations in patterns of care and outcomes of patients receiving invasive mechanical ventilation in China: a national cross-sectional survey [J]. J Thorac Dis, 2019, 11(7): 2878-2889.
[2]
Du B, An Y, Kang Y, et al. Characteristics of critically ill patients in ICUs in mainland China [J]. Crit Care Med, 2013, 41(1): 84-92.
[3]
Stein SW, Thiel CG. The history of therapeutic aerosols: a chronological review [J]. J Aerosol Med Pulm Drug Deliv, 2017, 30(1): 20-41.
[4]
Dhanani J, Fraser JF, Chan HK, et al. Fundamentals of aerosol therapy in critical care [J]. Crit Care, 2016, 20(1): 269.
[5]
Plotnikow GA, Accoce M, Navarro E, et al. Humidification and heating of inhaled gas in patients with artificial airway. A narrative review [J]. Rev Bras Ter Intensiva, 2018, 30(1): 86-97.
[6]
Zhang Z, Xu P, Fang Q, et al. Practice pattern of aerosol therapy among patients undergoing mechanical ventilation in mainland China: A web-based survey involving 447 hospitals [J]. PLoS One, 2019, 14(8): e0221577.
[7]
Moustafa IOF, ElHansy MHE, Al Hallag M, et al. Clinical outcome associated with the use of different inhalation method with and without humidification in asthmatic mechanically ventilated patients [J]. Pulm Pharmacol Ther, 2017, 45: 40-46.
[8]
Galindo-Filho VC, Alcoforado L, Rattes C, et al. A mesh nebulizer is more effective than jet nebulizer to nebulize bronchodilators during non-invasive ventilation of subjects with COPD: A randomized controlled trial with radiolabeled aerosols [J]. Respir Med, 2019, 153: 60-67.
[9]
Galindo-Filho VC, Ramos ME, Rattes CS, et al. Radioaerosol pulmonary deposition using mesh and jet nebulizers during noninvasive ventilation in healthy subjects [J]. Respir Care, 2015, 60(9): 1238-1246.
[10]
Dhand R. How should aerosols be delivered during invasive mechanical ventilation? [J]. Respir Care, 2017, 62(10): 1343-1367.
[11]
Phipps PR, Gonda I. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration [J]. Chest, 1990, 97(6): 1327-1332.
[12]
Hess D, Fisher D, Williams P, et al. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand [J]. Chest, 1996, 110(2): 498-505.
[13]
Ari A, Atalay OT, Harwood R, et al. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation [J]. Respir Care, 2010, 55(7): 845-851.
[14]
Sutherasan Y, Ball L, Raimondo P, et al. Effects of ventilator settings, nebulizer and exhalation port position on albuterol delivery during non-invasive ventilation: an in-vitro study [J]. BMC Pulm Med, 2017, 17(1): 9.
[15]
Dugernier J, Ehrmann S, Sottiaux T, et al. Aerosol delivery during invasive mechanical ventilation: a systematic review [J]. Crit Care, 2017, 21(1): 264.
[16]
Moustafa IOF, Ali MRA, Al Hallag M, et al. Lung deposition and systemic bioavailability of different aerosol devices with and without humidification in mechanically ventilated patients [J]. Heart Lung, 2017, 46(6): 464-467.
[17]
Moraine JJ, Truflandier K, Vandenbergen N, et al. Placement of the nebulizer before the humidifier during mechanical ventilation: Effect on aerosol delivery [J]. Heart Lung, 2009, 38(5): 435-439.
[18]
冉碧勤, 谭道琼. 有创呼吸机不同雾化器位置的气道疗效对比 [J]. 中国继续医学教育, 2017, 9(4): 247-248.
[19]
江源源, 胡蕾, 刘敏, 等. 不同雾化位置对机械通气患者气道治疗的影响 [J]. 巴楚医学, 2019, 2(3): 99-102+115.
[20]
温敏, 郑凤梅, 李桂贤, 等. 雾化器不同位置对机械通气病人气道疗效的观察 [J]. 全科护理, 2011, 9(15): 1324-1325.
[21]
Ari A, Areabi H, Fink JB. Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation [J]. Respir Care, 2010, 55(7): 837-844.
[22]
Mouloudi E, Katsanoulas K, Anastasaki M, et al. Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of tidal volume [J]. Intensive Care Med, 1999, 25(11): 1215-1221.
[23]
Dugernier J, Reychler G, Wittebole X, et al. Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study [J]. Ann Intensive Care, 2016, 6(1): 73.
[24]
Mouloudi E, Prinianakis G, Kondili E, et al. Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of flow pattern [J]. Eur Respir J, 2000, 16(2): 263-268.
[25]
王琳, 关纯, 秦贤, 等. 不同模式与参数设置下机械通气时雾化吸入对呼吸力学指标的影响 [J]. 中华危重病急救医学, 2018, 30(11): 1036-1040.
[26]
Mouloudi E, Katsanoulas K, Anastasaki M, et al. Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of end-inspiratory pause [J]. Eur Respir J, 1998, 12(1): 165-169.
[27]
徐小雅, 江美芳, 王永生, 等. 氧气驱动雾化吸入联合无创呼吸机治疗在COPD合并呼吸衰竭患者中的应用及护理 [J]. 四川医学, 2013, 34(7): 1099-1101.
[28]
曾宇红, 姚赟, 沈佩雷, 等. 经无创呼吸机雾化吸入治疗AECOPD合并Ⅱ型呼吸衰竭的临床观察 [J]. 药品评价, 2016, 13(20): 47-49.
[29]
郄国玲, 韩江玲, 张换春, 等. 不同雾化方式在慢性阻塞性肺疾病患者无创通气中的疗效观察 [J]. 护士进修杂志, 2014, 29(11): 1014-1016.
[30]
彭晓卉. 无创呼吸机联合氧气驱动雾化吸入治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的临床疗效 [J]. 临床合理用药杂志, 2018, 11(9): 113-114.
[31]
粟玲, 沈瑶, 杨叶梦, 等. 无创机械通气串联雾化吸入治疗老年慢性阻塞性肺疾病急性加重期合并Ⅱ型呼吸衰竭的临床观察 [J]. 老年医学与保健, 2020, 26(2): 245-249.
[32]
李登媛, 周向东. 无创通气联合不同时机雾化吸入治疗AECOPD合并Ⅱ型呼吸衰竭患者的疗效对比 [J]. 现代医药卫生, 2016, 32(6): 833-835.
[33]
Nava S, Karakurt S, Rampulla C, et al. Salbutamol delivery during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease: a randomized, controlled study [J]. Intensive Care Med, 2001, 27(10): 1627-1635.
[34]
彭磊, 宋燕燕, 王祺东, 等. 无创正压通气串联雾化吸入治疗对AECOPD合并2型呼吸衰竭患者的疗效分析 [J]. 系统医学, 2017, 2(7): 57-60.
[35]
孙文欣, 庄凤艳, 万梅. 两种时机应用氧气驱动雾化吸入在无创正压通气治疗COPD患者中的疗效观察 [J]. 中国继续医学教育, 2015, 7(20): 137-138.
[36]
武玉斌, 吴祖凤. 不同雾化方式在Ⅱ型呼吸衰竭的疗效观察 [J]. 安徽医药, 2015, 19(04): 806-808.
[37]
俞亦好, 戴新建. 2种雾化吸入法的效果比较 [J]. 中国实用护理杂志, 2009, (8): 36-37.
[38]
Abdelrahim ME, Plant P, Chrystyn H. In-vitro characterisation of the nebulised dose during non-invasive ventilation [J]. J Pharm Pharmacol, 2010, 62(8): 966-972.
[39]
Branconnier MP, Hess DR. Albuterol delivery during noninvasive ventilation [J]. Respir Care, 2005, 50(12): 1649-1653.
[40]
Calvert LD, Jackson JM, White JA, et al. Enhanced delivery of nebulised salbutamol during non-invasive ventilation [J]. J Pharm Pharmacol, 2006, 58(11): 1553-1557.
[41]
Chatmongkolchart S, Schettino GP, Dillman C, et al. In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position [J]. Crit Care Med, 2002, 30(11): 2515-2519.
[42]
Dai B, Kang J, Sun LF, et al. Influence of exhalation valve and nebulizer position on albuterol delivery during noninvasive positive pressure ventilation [J]. J Aerosol Med Pulm Drug Deliv, 2014, 27(2): 125-132.
[43]
Haw A, McPeck M, Cuccia AD, et al. Face mask leak determines aerosol delivery in noninvasive ventilation [J]. Respir Care, 2021, 66(1): 95-103.
[44]
Michotte JB, Jossen E, Roeseler J, et al. In vitro comparison of five nebulizers during noninvasive ventilation: analysis of inhaled and lost doses [J]. J Aerosol Med Pulm Drug Deliv, 2014, 27(6): 430-440.
[45]
Peng Y, Dai B, Hu CX, et al. Which nebulizer position should be avoided? an extended study of aerosol delivery and ventilator performance during noninvasive positive pressure ventilation [J]. Respiration, 2018, 95(3): 145-153.
[46]
Boe J, Dennis JH, O'Driscoll BR, et al. European Respiratory Society Guidelines on the use of nebulizers [J]. Eur Respir J, 2001, 18(1): 228-242.
[47]
van Meenen DMP, van der Hoeven SM, Binnekade JM, et al. Effect of on-demand vs routine nebulization of acetylcysteine with salbutamol on ventilator-free days in intensive care unit patients receiving invasive ventilation: a randomized clinical trial [J]. Jama, 2018, 319(10): 993-1001.
[48]
Wu SH, Shyu LJ, Li CH, et al. Better airway resistance reduction profile in intubated COPD patients by personalized bronchodilator dosing: A pilot randomized control trial [J]. Pulm Pharmacol Ther, 2018, 49: 134-139.
[49]
Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group [J]. Chest, 1997, 112(6): 1514-1521.
[50]
Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019 [J]. Eur Respir J, 2019, 53(5).
[51]
Beltaief K, Msolli MA, Zorgati A, et al. Nebulized terbutaline and ipratropium bromide versus terbutaline alone in acute exacerbation of chronic obstructive pulmonary disease requiring noninvasive ventilation: a randomized double-blind controlled trial [J]. Acad Emerg Med, 2019, 26(4): 434-442.
[52]
Riise GC, Qvarfordt I, Larsson S, et al. Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro [J]. Respiration, 2000, 67(5): 552-558.
[53]
Pérez-Giraldo C, Rodríguez-Benito A, Morán FJ, et al. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis [J]. J Antimicrob Chemother, 1997, 39(5): 643-646.
[54]
Kashef N, Karami S, Djavid GE. Phototoxic effect of hypericin alone and in combination with acetylcysteine on Staphylococcus aureus biofilms [J]. Photodiagnosis Photodyn Ther, 2015, 12(2): 186-192.
[55]
Arshad Q, Asghar S, Shafqat E, et al. Role of N-Acetylcysteine in clearance of secretions in mechanical ventilated patients [J]. 2019.
[56]
Masoompour SM, Anushiravani A, Tafaroj Norouz A. Evaluation of the effect of nebulized N-Acetylcysteine on respiratory secretions in mechanically ventilated patients: randomized clinical trial [J]. Iran J Med Sci, 2015, 40(4): 309-315.
[57]
鲍洁. N-乙酰半胱氨酸在ARDS中的应用评价 [J]. 医药论坛杂志, 2015, 36(12): 137-138.
[58]
Abdellatif S, Trifi A, Daly F, et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial [J]. Ann Intensive Care, 2016, 6(1): 26.
[59]
Hassan NA, Awdallah FF, Abbassi MM, et al. Nebulized Versus Ⅳ Amikacin as adjunctive antibiotic for hospital and ventilator-acquired pneumonia postcardiac surgeries: a randomized controlled trial [J]. Crit Care Med, 2018, 46(1): 45-52.
[60]
Kollef MH, Ricard JD, Roux D, et al. A randomized trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-negative ventilator-associated pneumonia: IASIS trial [J]. Chest, 2017, 151(6): 1239-1246.
[61]
Liu C, Zhang YT, Peng ZY, et al. Aerosolized Amikacin as adjunctive therapy of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a single-center randomized controlled Trial [J]. Chin Med J (Engl), 2017, 130(10): 1196-1201.
[62]
Lu Q, Yang J, Liu Z, et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa [J]. Am J Respir Crit Care Med, 2011, 184(1): 106-115.
[63]
Moradi Moghaddam O, Niakan Lahiji M, Talebi-Taher M, et al. Effect of inhaled colistin on the treatment of ventilator-associated pneumonia due to multi-drug resistant acinetobacter [J]. Tanaffos, 2019, 18(1): 66-73.
[64]
Niederman MS, Chastre J, Corkery K, et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia [J]. Intensive Care Med, 2012, 38(2): 263-271.
[65]
Niederman MS, Alder J, Bassetti M, et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial [J]. Lancet Infect Dis, 2020, 20(3): 330-340.
[66]
Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria [J]. J Antimicrob Chemother, 2010, 65(12): 2645-2649.
[67]
Stokker J, Karami M, Hoek R, et al. Effect of adjunctive tobramycin inhalation versus placebo on early clinical response in the treatment of ventilator-associated pneumonia: the VAPORISE randomized-controlled trial [J]. Intensive Care Med, 2020, 46(3): 546-548.
[68]
Hallal A, Cohn SM, Namias N, et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study [J]. Surg Infect (Larchmt), 2007, 8(1): 73-82.
[69]
王昕华, 赵弘卿. 抗生素不同给药方式治疗呼吸机相关性肺炎的临床观察 [J]. 中国药业, 2015, 24(23): 46-48.
[70]
岳新召. 雾化吸入阿米卡星治疗呼吸机相关性肺炎的疗效及可行性研究 [J]. 临床合理用药杂志, 2016, 9(15): 38-39-42.
[71]
张文. 妥布霉素雾化吸入联合静脉使用抗生素治疗呼吸机相关性肺炎有效性和安全性观察 [J]. 中国社区医师, 2020, 36(14): 64-66.
[72]
Khorvash F, Yaghoubi S, Farsaei S, et al. Comparison of two therapeutic approaches for the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter: a randomized clinical trial study [J]. J Immunoassay Immunochem, 2020, 41(1): 97-105.
[73]
Montgomery AB, Vallance S, Abuan T, et al. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients [J]. J Aerosol Med Pulm Drug Deliv, 2014, 27(6): 441-448.
|